What is the current market valuation of the hematopoietic stem-cell-transplantation market in France?

The market valuation was $200.1 Million in 2024. Read More

What is the projected market size for the hematopoietic stem-cell-transplantation market in France by 2035?

The projected market size is $700.0 Million by 2035. Read More

What is the expected CAGR for the hematopoietic stem-cell-transplantation market in France during the forecast period 2025 - 2035?

The expected CAGR is 12.06% during the forecast period 2025 - 2035. Read More

Which companies are the key players in the France hematopoietic stem-cell-transplantation market?

Key players include Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda Pharmaceutical, Roche, Merck & Co., and AstraZeneca. Read More

What are the main types of transplants in the France hematopoietic stem-cell-transplantation market?

The main types of transplants are allogeneic and autologous, with valuations of $80.0 Million and $120.1 Million in 2024, respectively. Read More

What indications are most prevalent in the France hematopoietic stem-cell-transplantation market?

The most prevalent indications include Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, and Multiple Myeloma, with respective valuations of $40.0 Million, $30.0 Million, and $50.0 Million in 2024. Read More

What applications are utilized in the France hematopoietic stem-cell-transplantation market?

The applications include Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, and Cord Blood Transplant, with valuations of $60.0 Million, $80.0 Million, and $60.1 Million in 2024. Read More

How does the market for autologous transplants compare to allogeneic transplants in France?

In 2024, the market for autologous transplants was valued at $120.1 Million, while allogeneic transplants were valued at $80.0 Million. Read More

What is the growth potential for the hematopoietic stem-cell-transplantation market in France?

The market appears to have substantial growth potential, projected to reach $700.0 Million by 2035. Read More

What factors might influence the growth of the hematopoietic stem-cell-transplantation market in France?

Factors influencing growth may include advancements in treatment technologies, increasing prevalence of hematological disorders, and the strategic initiatives of key players. Read More

France Hematopoietic Stem Cell Transplantation Market

ID: MRFR/LS/48280-HCR

200 Pages

Nidhi Mandole

Last Updated: April 24, 2026

France Hematopoietic Stem Cell Transplantation Market Research Report: Size, Share, Trend Analysis By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Applications (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth Outlook & Industry Forecast 2025 To 2035

France Hematopoietic Stem Cell Transplantation Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Transplant Type (USD Million)
  1. 4.1.1 Allogeneic
  2. 4.1.2 Autologous
2. 4.2 Industrial Automation & Equipment, BY Indication (USD Million)
  1. 4.2.1 Acute Myeloid Leukemia
  2. 4.2.2 Acute Lymphoblastic Leukemia
  3. 4.2.3 Hodgkin Lymphoma
  4. 4.2.4 Non-Hodgkin Lymphoma
  5. 4.2.5 Multiple Myeloma
  6. 4.2.6 Other Non-Malignant Disorders
3. 4.3 Industrial Automation & Equipment, BY Application (USD Million)
  1. 4.3.1 Bone Marrow Transplant
  2. 4.3.2 Peripheral Blood Stem Cells Transplant
  3. 4.3.3 Cord Blood Transplant
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Celgene (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Takeda Pharmaceutical (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 FRANCE MARKET ANALYSIS BY TRANSPLANT TYPE
3. 6.3 FRANCE MARKET ANALYSIS BY INDICATION
4. 6.4 FRANCE MARKET ANALYSIS BY APPLICATION
5. 6.5 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
8. 6.8 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TRANSPLANT TYPE, 2024 (% SHARE)
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TRANSPLANT TYPE, 2024 TO 2035 (USD Million)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 (% SHARE)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 TO 2035 (USD Million)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 (% SHARE)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY APPLICATION, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TRANSPLANT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

France Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Transplant Type (USD Million, 2025-2035)

Allogeneic
Autologous

Industrial Automation & Equipment By Indication (USD Million, 2025-2035)

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Other Non-Malignant Disorders

Industrial Automation & Equipment By Application (USD Million, 2025-2035)

Bone Marrow Transplant
Peripheral Blood Stem Cells Transplant
Cord Blood Transplant

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”